July 10, 2012
Last month Pharmaceutical Executive published a summary based on its annual panel of heavy hitters in business development on best practices in licensing and M&A for the year ahead. The discussion was built around the latest findings from Cambell Alliance's 2012 Survey of Dealmaker Intentions. The survey had many interesting conclusions, and I thought that I would summarize a few of their thoughts here - I recommend reading the full article.
Most attractive in-licensing therapy areas
In-licensors expects most deals to be made in oncology, cardiovascular, CNS, metabolic and respiratory drugs.